Amgen (NASDAQ:AMGN) received a $200.00 target price from investment analysts at Mizuho in a report issued on Tuesday. The brokerage presently has a “buy” rating on the medical research company’s stock. Mizuho’s price objective suggests a potential upside of 14.40% from the company’s previous close.
Several other research firms also recently commented on AMGN. Argus raised Amgen from a “hold” rating to a “buy” rating and increased their price objective for the company from $192.33 to $220.00 in a report on Tuesday, January 23rd. JPMorgan Chase increased their price objective on Amgen from $184.00 to $189.00 and gave the company a “neutral” rating in a report on Wednesday, January 24th. Royal Bank of Canada reissued a “hold” rating and issued a $189.00 price objective on shares of Amgen in a report on Wednesday, January 24th. Vetr downgraded Amgen from a “hold” rating to a “sell” rating and set a $181.60 price objective for the company. in a report on Tuesday, March 6th. Finally, Piper Jaffray cut their price objective on Amgen from $194.00 to $190.00 and set an “overweight” rating for the company in a report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and ten have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $190.48.
NASDAQ AMGN opened at $174.83 on Tuesday. The company has a market capitalization of $116,720.13, a PE ratio of 13.90, a P/E/G ratio of 2.14 and a beta of 1.36. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17. Amgen has a 12 month low of $152.16 and a 12 month high of $201.23.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, April 24th. The medical research company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.24 by $0.23. The company had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.44 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The firm’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.15 EPS. sell-side analysts forecast that Amgen will post 13.28 earnings per share for the current year.
Amgen declared that its board has authorized a stock repurchase program on Thursday, February 1st that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Friday, March 16th. The stock was sold at an average price of $189.75, for a total transaction of $289,368.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 4,575 shares of company stock worth $818,330 in the last quarter. Company insiders own 0.27% of the company’s stock.
A number of hedge funds have recently bought and sold shares of AMGN. Lingohr & Partner Asset Management GmbH increased its position in Amgen by 71.4% during the 2nd quarter. Lingohr & Partner Asset Management GmbH now owns 8,165 shares of the medical research company’s stock worth $1,340,000 after buying an additional 3,400 shares during the period. Thrivent Financial For Lutherans increased its position in Amgen by 107.1% during the 2nd quarter. Thrivent Financial For Lutherans now owns 118,342 shares of the medical research company’s stock worth $20,382,000 after buying an additional 61,212 shares during the period. Verity Asset Management Inc. increased its position in Amgen by 363.8% during the 2nd quarter. Verity Asset Management Inc. now owns 8,989 shares of the medical research company’s stock worth $1,548,000 after buying an additional 7,051 shares during the period. Investec Asset Management LTD increased its position in Amgen by 1,081.7% during the 2nd quarter. Investec Asset Management LTD now owns 21,967 shares of the medical research company’s stock worth $3,783,000 after buying an additional 20,108 shares during the period. Finally, Fort L.P. bought a new position in Amgen during the 2nd quarter worth $4,294,000. Hedge funds and other institutional investors own 85.76% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/26/amgen-amgn-given-a-200-00-price-target-at-mizuho.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.